Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine in treatment-resistant OCD
NCT01371110Phase 2Terminated
- Start
- Jun 2012
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of ketamine in obsessive compulsive disorder (OCD). Primary endpoint: Yale-Brown Obsessive Compulsive Scale at 24 hours. Started Jun 2012; status: terminated.
02
Drugs
ketamine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT01371110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01371110.